Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$5.24 ▼ -0.12
(-2.24%)
MKT CAP: $950.4M • VOL: 10.35M
52W L $3 52W H $6
PRME // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $4.6M | $3.0M | $0 |
| YoY Revenue Growth % | +55.3% | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$208.3M | -$202.5M | -$204.8M |
| Operating Margin % | -80.0% | -80.0% | — |
| Net Income (GAAP) | -$201.1M | -$195.9M | -$198.1M |
| EBITDA (Normalized) | -$204.7M | -$196.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$162.6M | -$122.9M | -$165.4M |
| Capital Expenditures (CapEx) | $4.5M | $7.3M | — |
| Free Cash Flow (FCF) | -$167.1M | -$130.2M | -$165.4M |
| FCF Margin % | -80.0% | -80.0% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $63.0M | $182.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $120.9M | $153.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PRME.